Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.94 SEK | -1.67% | +10.33% | -79.39% |
Mar. 28 | Elicera Therapeutics AB Announces Director Changes | CI |
Mar. 06 | Elicera Enters Agreement with Prominent US Cancer Center to Evaluate the Use of ITANK in T-Cell Receptor Therapies | CI |
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 32.99M 3.07M |
---|---|---|---|---|---|
Net income 2024 * | -48M -4.47M | Net income 2025 * | -34M -3.17M | EV / Sales 2024 * | - |
Net cash position 2024 * | 35M 3.26M | Net cash position 2025 * | 41M 3.82M | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-0.39
x | P/E ratio 2025 * |
-0.55
x | Employees | 2 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 38.42% |
1 day | -1.67% | ||
1 week | +10.33% | ||
1 month | -21.34% | ||
3 months | -46.13% | ||
6 months | -81.05% | ||
Current year | -79.39% |
Managers | Title | Age | Since |
---|---|---|---|
Magnus Essand
FOU | Founder | 60 | 13-12-31 |
Di Yu
FOU | Founder | 39 | 13-12-31 |
Jamal El-Mosleh
CEO | Chief Executive Officer | 43 | 13-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 63 | 19-12-31 | |
Director/Board Member | 73 | 19-12-31 | |
Chairman | 68 | 19-12-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-23 | 0.94 | -1.67% | 80,830 |
24-05-22 | 0.956 | -2.85% | 161,266 |
24-05-21 | 0.984 | -1.40% | 257,257 |
24-05-20 | 0.998 | -6.29% | 448,415 |
24-05-17 | 1.065 | +8.67% | 609,025 |
Delayed Quote Nasdaq Stockholm, May 23, 2024 at 11:14 am EDT
More quotesEPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-79.39% | 3.13M | |
+38.69% | 723B | |
+34.28% | 595B | |
-4.49% | 369B | |
+20.24% | 332B | |
+2.12% | 282B | |
+17.02% | 244B | |
+9.31% | 208B | |
-5.07% | 205B | |
-0.35% | 168B |
- Stock Market
- Equities
- ELIC Stock